Who is the CEO of ObsEva SA?

Mr. Fabien Lefebvre de Ladonchamps is a business executive who currently serves as the CEO of ObsEva SA.

What is the Revenue Growth of ObsEva SA?

Revenue growth data for ObsEva SA is currently unavailable.

What is ObsEva SA operating Margin?

ObsEva SA operating margin is -79.83% which shows how much profit OBSN.SW earns from each dollar of sales, after subtracting the direct costs tied to generating that revenue.

In which market sector does ObsEva SA operate?

ObsEva SA falls under the Healthcare sector which thrives across multiple industries. It stays competitive through its diverse product lineup, which spans computer hardware, tech gadgets, video streaming services, and cloud computing solutions.

What is ObsEva SA revenue growth?

Revenue growth data for ObsEva SA is currently unavailable.

ObsEva SA

OBSN.SW•SIX

HealthcareBiotechnology

$0.001

$-0.00(-76.92%)

ObsEva SA (OBSN.SW) Stock Overview

Explore ObsEva SA’s financial performance, market position, analyst ratings, and future outlook.

Stats data is not available for OBSN.SWStats details for OBSN.SW are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Analyst Recommendations data is not available for OBSN.SWAnalyst Recommendations details for OBSN.SW are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

ObsEva SA, a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. It is developing Linzagolix, an oral gonadotropin releasing hormone receptor antagonist that is in Phase III clinical trial for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. The company is also involved in developing Ebopiprant, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, which is in Phase II clinical trial as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age; and Nolasiban, an oral oxytocin receptor antagonist that is in Phase I clinical trial to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization. ObsEva SA was founded in 2012 and is headquartered in Geneva, Switzerland.

CEO

Mr. Fabien Lefebvre de Ladonchamps

Employees

Headquarters

Chemin des Aulx, 12, Geneva

Founded

2018